These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. For research use only.  Legal & Disclaimer

Modified GRF 1-29 · GHRH Receptor Agonist

CJC-1295 Research Compound

CJC-1295 without DAC (Mod GRF 1-29) is a synthetic 29-amino acid GHRH analog engineered with four amino acid substitutions for enhanced receptor binding stability. Available in 5mg and 10mg research sample sizes. HPLC + MS verified by Krause Analytical. For research use only. Not for human use.

5mg 10mg COA — Krause Analytical Reviewed — Sabrina Runbeck PA-C Finnrick Pulse
View Products & Pricing View COA Library

Compound Overview

What Is CJC-1295?

CJC-1295 without DAC — also cataloged as Modified GRF(1-29) or Mod GRF 1-29 — is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) consisting of 29 amino acids. It is derived from the native GHRH(1-29) sequence with four strategic amino acid substitutions designed to confer improved proteolytic resistance and enhanced binding at the GHRH receptor.

The four substitution modifications distinguish CJC-1295 from the native GHRH fragment. These substitutions replace amino acids at positions 2, 8, 15, and 27 — positions historically vulnerable to endogenous peptidase activity — with non-native residues that resist cleavage while preserving receptor agonist activity. Published research has examined how these modifications affect receptor affinity and in-vitro binding kinetics relative to the parent GHRH(1-29) fragment.

Without DAC refers to the absence of a Drug Affinity Complex (DAC) — a lysine-based linker-albumin binding moiety appended to the longer CJC-1295 variant. The version without DAC retains a shorter biological half-life in research models (approximately 30 minutes), producing a more pulsatile GH axis signaling profile compared to the DAC-extended form. This kinetic distinction makes CJC-1295 without DAC a distinct research tool for studies examining pulsatile versus continuous GHRH receptor activation patterns.

Sequence Labs offers CJC-1295 without DAC as a research-grade lyophilized compound verified by HPLC and mass spectrometry. It is classified strictly as a research compound. For research use only. Not for human use.

Compound Specifications
Common Name CJC-1295 w/o DAC
Also Known As Mod GRF 1-29
Class GHRH Analog
Sequence Length 29 amino acids
Molecular Formula C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight ~3367 Da
CAS Number 863288-34-0
Half-Life (research) ~30 min
Form Lyophilized powder
Purity ≥98% (HPLC verified)
Testing HPLC + MS · Krause Analytical
Available Sizes 5mg · 10mg
Classification Research use only

Published Research

Research Background

Published research has examined CJC-1295 and related GHRH analogs across several preclinical and mechanistic contexts. The following areas represent active domains in the peer-reviewed literature.

01
GHRH Receptor Mechanism Research
Published research has examined how CJC-1295 engages the GHRH receptor (GHRH-R) at the molecular level. Studies have characterized the receptor binding kinetics, cAMP signaling cascade activation, and downstream intracellular effects in pituitary cell line models — providing foundational data on GHRH analog agonist activity.
02
GH Axis Pulsatile Research in Preclinical Models
The shorter half-life profile of CJC-1295 without DAC has been studied in rodent preclinical models for its relationship to pulsatile GH secretion dynamics. Published research has examined how pulsatile GHRH-R stimulation at defined intervals affects the amplitude and frequency of GH secretory events in preclinical models.
03
Hypothalamic-Pituitary Axis Research
Published research has examined the role of synthetic GHRH analogs in modulating hypothalamic-pituitary axis signaling in preclinical models. Studies have investigated feedback dynamics within the GHRH–somatostatin axis and the interaction of exogenous GHRH analogs with endogenous regulatory circuits.
04
CJC-1295 + Ipamorelin Dual Pathway Research
Published research has examined the combination of CJC-1295 and Ipamorelin in preclinical models, given their complementary receptor targets — GHRH-R and GHS-R1a respectively. Studies have explored whether simultaneous engagement of both receptor pathways produces distinct or additive GH axis signaling profiles compared to single-compound research paradigms.
05
Receptor Binding Kinetics Research
The four amino acid substitutions in CJC-1295 have been the subject of receptor binding kinetics studies, comparing affinity and selectivity at the GHRH receptor versus native GHRH(1-29) and other synthetic GHRH fragments. Published research has measured binding constants and displacement activity in pituitary receptor binding assays.
Browse CJC-1295 literature on PubMed

Research Distinction

CJC-1295 with DAC vs. Without DAC — Understanding the Research Difference

The two variants of CJC-1295 represent distinct research tools with meaningfully different pharmacokinetic profiles. Understanding the distinction is important for accurate study design and literature interpretation.

This Product
CJC-1295 Without DAC
(Mod GRF 1-29)
  • No Drug Affinity Complex — no albumin binding modification
  • Shorter half-life in research models (~30 minutes)
  • Produces a pulsatile GHRH-R activation profile
  • More closely mimics endogenous pulsatile GHRH release patterns in preclinical models
  • Often studied alongside Ipamorelin (GHS-R1a pathway)
  • CAS: 863288-34-0
Alternate Form
CJC-1295 With DAC
(DAC-GRF)
  • Includes a lysine-DAC linker enabling albumin binding
  • Extended half-life in research models (days)
  • Produces a sustained, non-pulsatile GHRH-R activation profile
  • Studied in research contexts examining prolonged GH axis stimulation
  • Distinct research kinetics — not interchangeable with without-DAC form
  • Different CAS number — verify for each study protocol

Research note: These variants are not interchangeable in research protocols. Selecting between them depends on whether the study design requires pulsatile or sustained GHRH receptor engagement. Published research has examined each variant independently; conflating the two in literature review or study design may introduce methodological inconsistency.

Sequence Labs Supply

CJC-1295 Research Samples

Every batch independently verified by Krause Analytical (HPLC + mass spectrometry). Catalog reviewed by Sabrina Runbeck, PA-C. Finnrick Pulse quality assurance.

Research Sample
CJC-1295 without DAC
5mg
$40 / vial
  • 5mg lyophilized research sample
  • HPLC + MS verified — Krause Analytical
  • COA available on request
  • ≥98% purity verified
  • Reviewed by Sabrina Runbeck, PA-C
  • Finnrick Pulse quality assurance
Order 5mg
Research Sample — Best Value
CJC-1295 without DAC
10mg
$65 / vial
  • 10mg lyophilized research sample
  • HPLC + MS verified — Krause Analytical
  • COA available on request
  • ≥98% purity verified
  • Reviewed by Sabrina Runbeck, PA-C
  • Finnrick Pulse quality assurance
Order 10mg
For research use only. Not for human use. Wholesale and bulk research orders available — contact us for tiered pricing. Venmo, Zelle, Bitcoin, and Wire/ACH accepted.

Lab Reference

Reconstitution Reference

For research use only — Not for human use
01
Prepare the solvent
Bacteriostatic water (BAC water) is the standard solvent for lyophilized GHRH analog research samples. Confirm solvent sterility and integrity before use in any research protocol.
02
Introduce solvent slowly
Introduce the solvent along the interior glass wall of the vial — not directly onto the lyophilized research sample cake. This technique reduces disruption to the peptide structure during the reconstitution process.
03
Allow to dissolve
Allow the solution to dissolve at room temperature. Gentle swirling is acceptable; avoid vigorous agitation or vortex mixing, which may degrade sensitive peptide research samples.
04
Store per protocol
Reconstituted research samples should be stored under appropriate laboratory conditions as specified in your research protocol. Consult published stability data for GHRH analog peptide solutions in your storage format.

These reconstitution notes are provided for general laboratory reference only. They do not constitute medical advice, clinical guidance, or a protocol endorsement. Sequence Labs compounds are strictly for qualified research use. Not for human use, not for veterinary use, and not for human consumption. Researchers should consult their institution's protocols and applicable regulatory guidance before use.

Frequently Asked Questions

CJC-1295 is a synthetic 29-amino acid peptide analog of growth hormone-releasing hormone (GHRH). Developed with four amino acid substitutions for improved proteolytic resistance, it is classified as a GHRH receptor agonist and is used as a research compound in preclinical and in-vitro studies. Sequence Labs offers CJC-1295 without DAC (Mod GRF 1-29) in 5mg and 10mg research sample sizes. For research use only. Not for human use.
CJC-1295 without DAC (Mod GRF 1-29) lacks the Drug Affinity Complex modification that extends the half-life of the DAC variant. Without DAC, the half-life in research models is approximately 30 minutes, producing a pulsatile signaling profile at the GHRH receptor. The DAC version includes a lysine-albumin binding linker, extending its half-life to several days and producing sustained GHRH-R activation. The two forms are not interchangeable in research protocol design. For research use only. Not for human use.
Published research has examined CJC-1295 and Ipamorelin in combination in preclinical models. The two compounds engage distinct receptor systems: CJC-1295 acts at the GHRH receptor (GHRH-R), while Ipamorelin targets the growth hormone secretagogue receptor 1a (GHS-R1a). Dual-pathway studies have examined whether simultaneous receptor engagement produces differential GH axis signaling compared to either compound researched alone. Both compounds are available separately from Sequence Labs. For research use only. Not for human use.
Sequence Labs carries CJC-1295 without DAC in 5mg ($40) and 10mg ($65) research sample sizes. Both sizes are independently tested by Krause Analytical using HPLC and mass spectrometry, with COAs available in the Sequence Labs COA Library. Wholesale pricing is available for qualified researchers — contact us for tiered bulk rates. For research use only. Not for human use.
For research purposes, the lyophilized CJC-1295 research sample is typically reconstituted by introducing bacteriostatic water as the solvent. The solvent should be introduced slowly along the vial wall rather than directly onto the peptide cake. The solution is then allowed to dissolve gently at room temperature before use in the research protocol. These are general laboratory reference notes only — researchers should follow their institution's applicable protocols. For research use only. Not for human use.
No. CJC-1295 sold by Sequence Labs is strictly for research use only. It is not approved for human use, is not an FDA-evaluated drug or supplement, and is not intended for self-administration, clinical use, or any application involving human subjects outside of formally approved research protocols governed by an IRB or equivalent oversight body. All Sequence Labs compounds are sold exclusively for qualified in-vitro and preclinical research purposes. Not for human use.

Ready to source CJC-1295 for your research?

HPLC + MS verified by Krause Analytical. Reviewed by Sabrina Runbeck, PA-C. Available in 5mg and 10mg research sample sizes.

View Products & Pricing Ipamorelin Research Page Contact Us